In the early 1990s, Ikeyama et al introduced a human MRP-1/CD9 complementary DNA plasmid into several cancer cell lines and found the suppression of cell motility following transfection, suggesting that CD9 renders tumor cells more static in vivo, consequently resulting in the suppression of tumor metastasis (8). The gene discussed is CD9; the disease is cancer.